Clinical trials: Mild to Moderate COVID-19
Mild to Moderate COVID-19
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
- Trial name
- COMBAAT (NCT04705844)
- Testing
- Adalimumab
- Sponsor
- Alachua Government Services, Inc.
Coronavirus Infection, COVID
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients…
- Conditions
- Coronavirus Infection, COVID, Sars-CoV2
- Trial name
- SIZI-COVID-PK (NCT04472585)
- Testing
- Ivermectin Injectable Solution, Zinc, Oral Ivermectin
- Where
- 2 sites in Pakistan
- Volunteers
- 180 people
- Sponsor
- Sohaib Ashraf
COVID - 19
Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus
Patients with COVID-19 which are 60 years old or above or with comorbidities are at risk of deteriorating and developing severe illness.
- Trial name
- COSTA (NCT04355052)
- Testing
- hydroxychloroquine in combination with camostat mesylate, Hydroxychloroquine in combination of Azithromycin
- Where
- 2 sites in Israel
- Volunteers
- 250 people
- Sponsor
- Sheba Medical Center
COVID-19
An Observational Study in Patients With Mild to Moderate COVID-19
The purpose of this study was to observe real-world disease progression in mild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illness or death.
- Trial name
- NCT05366244
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pudong Hospital
Dementia, Mild Cognitive Impairment
Virtual Chair Yoga for Older Adults and Caregivers: Randomized Controlled Trial
Over 700,000 Canadians are affected by dementia costing the health care system approximately $10 billion/year. Due to COVID-19, the government has urged individuals over the age of 70 to stay home, putting this population at risk…
- Trial name
- NCT04884529
- Testing
- Chair-yoga program
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Lady Davis Institute
Covid19, SARS (Disease)
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease.
- Trial name
- E-SPERANZA (NCT04695704)
- Testing
- Montelukast
- Where
- 8 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
COVID-19
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05758519
- Testing
- QLS1128
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
COVID-19
Effectiveness and Safety of New Oral Antivirals for COVID-19
There is an increased lack of short- and long-term real-life effectiveness and safety data on new oral antivirals authorised and commercialised to treat COVID-19.
- Trial name
- ESOA-19 (NCT05894603)
- Testing
- Nirmatrelvir/ritonavir, Molnupiravir
- Where
- 6 sites in Portugal
- Volunteers
- 211 people
- Sponsor
- Universidade do Porto
COVID-19, SARS CoV 2 Infection
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
ProLectin M is an orally administered polysaccharide. Polysaccharides competitively bind to the N-terminal tail of human galectin-3 through a proline isomerization [10].
- Trial name
- NCT05733780
- Testing
- Prolectin-M
- Volunteers
- 40 people
- Sponsor
- Bioxytran Inc.
Long COVID
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19.
- Trial name
- NCT06974058
- Testing
- Nasafytol® (Quercetin/Curcumin Supplement)
- Where
- Pakistan
- Volunteers
- 15 people
- Sponsor
- Liaquat University of Medical & Health Sciences
COVID-19
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.
- Trial name
- NCT05298813
- Testing
- IBIO123
- Where
- 11 sites in Brazil, South Africa
- Volunteers
- 162 people
- Sponsor
- Immune Biosolutions Inc
COVID19
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
- Trial name
- NCT04662671
- Testing
- RD-X19
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- EmitBio Inc.
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Catalysing the Containment of COVID-19
COVID-19 due to SARS-CoV-2 infection is a rapidly escalating global pandemic for which there is no proven effective treatment. COVID-19 is multi-dimensional disease caused by viral cytopathic effects and host-mediated…
- Trial name
- C3-RCT (NCT04523090)
- Testing
- Nitazoxanide
- Where
- 4 sites in South Africa
- Volunteers
- 322 people
- Sponsor
- University of Cape Town
COVID-19
Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19
This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial. It is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic (PK) profile of SHEN26 capsules in Chinese…
- Trial name
- NCT05676073
- Testing
- SHEN26 dose 1, SHEN26 dose 2
- Where
- 4 sites in China
- Volunteers
- 91 people
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
COVID-19, Hemodiafiltration
Immune Function in Elderly Patients With Mild to Moderate COVID-19 on Hemodialysis
This randomized controlled trial will focus on the effects of early oral nutritional supplementation on immune function in elderly patients with mild to moderate COVID-19 on maintenance hemodialysis.
- Trial name
- NCT05366205
- Testing
- Oral nutritional supplement, Nutrition consultation
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
COVID-19
JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects
JS016-002-Ib/II is a randomized, double-blinded, placebo-controlled study, to investigate the safety, PK profiles, preliminary efficacy and immunogenicity of intravenous Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody…
- Trial name
- NCT04780321
- Testing
- Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Covid19
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for…
- Trial name
- UNITED (NCT04656691)
- Testing
- bamlanivimab
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Daniel Griffin